Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 4/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | THRB | P10828 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 2/20 | 0.38 |
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.38 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | CA1 | P00915 | 1/20 | 0.36 |
| ▸ | CA2 | P00918 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1629454 | 0.82 | ALOX5 (0.34) | HTTTDP1ALDH1A1GAATHRB | |
| SCHEMBL1631356 | 0.81 | ALOX15 (0.34) | TDP1CYP3A4ALDH1A1THRBTSHR | |
| SCHEMBL1629974 | 0.80 | ALDH1A1 (0.36) | TDP1CYP3A4ALDH1A1THRBTSHR | |
| SCHEMBL4023643 | 0.80 | DPP8 (0.34) | ALDH1A1DPP7MEN1MAPTRAB9A | |
| SCHEMBL914891 | 0.80 | AKR1C3 (0.44) | CYP3A4ALDH1A1TSHRMEN1MAPT | |
| SCHEMBL1631592 | 0.79 | MAPK1 (0.37) | ALDH1A1TSHRMEN1RAB9AKMT2A | |
| SCHEMBL917313 | 0.78 | NPSR1 (0.46) | ALDH1A1GAATSHRMEN1KMT2A | |
| SCHEMBL641442 | 0.76 | ALDH1A1 (0.35) | TDP1ALDH1A1TSHRMAPT | |
| SCHEMBL23528125 | 0.75 | GAA (0.56) | HTTTDP1CYP3A4ALDH1A1GAA | |
| SCHEMBL30722357 | 0.75 | GAA (0.56) | HTTTDP1CYP3A4ALDH1A1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2183260-B1 | PHOSPHADIAZINE HCV POLYMERASE INHIBITORS IV | IDENIX PHARMACEUTICALS INC (US) | 2011-06-01 | — | — | EP | disclosed |
| US-7932240-B2 | Phosphadiazine HCV polymerase inhibitors IV | IDENIX PHARMACEUTICALS, INC. (US) | 2011-04-26 | — | — | US | disclosed |
| EP-2183260-A1 | PHOSPHADIAZINE HCV POLYMERASE INHIBITORS IV | IDENIX Pharmaceuticals, Inc. (US) | 2010-05-12 | — | — | EP | disclosed |
| US-20090081158-A1 | PHOSPHADIAZINE HCV POLYMERASE INHIBITORS IV | IDENIX PHARMACEUTICALS, INC. (US) | 2009-03-26 | — | — | US | disclosed |
| WO-2009032177-A1 | PHOSPHADIAZINE HCV POLYMERASE INHIBITORS I AND II | IDENIX PHARMACEUTICALS, INC. (US) | 2009-03-12 | — | — | WO | disclosed |
| WO-2009032179-A1 | PHOSPHADIAZINE HCV POLYMERASE INHIBITORS III AND VI | IDENIX PHARMACEUTICALS, INC. (US) | 2009-03-12 | — | — | WO | disclosed |
| WO-2009032180-A1 | PHOSPHADIAZINE HCV POLYMERASE INHIBITORS IV | IDENIX PHARMACEUTICALS, INC. (US) | 2009-03-12 | — | — | WO | disclosed |
| US-20090060866-A1 | PHOSPHADIAZINE HCV POLYMERASE INHIBITORS I AND II | IDENIX PHARMACEUTICALS, INC. (US) | 2009-03-05 | — | — | US | disclosed |
| US-20090060867-A1 | PHOSPHADIAZINE HCV POLYMERASE INHIBITORS III AND VI | IDENIX PHARMACEUTICALS, INC. (US) | 2009-03-05 | — | — | US | disclosed |
| US-20090060872-A1 | PHOSPHADIAZINE HCV POLYMERASE INHIBITORS V | IDENIX PHARMACEUTICALS, INC. (US) | 2009-03-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090081158-A1 | PHOSPHADIAZINE HCV POLYMERASE INHIBITORS IV | POLI, ITPA, POLR2H | HTT 4518/4885TDP1 2545/4885CYP3A4 834/4885 |
| US-20090060872-A1 | PHOSPHADIAZINE HCV POLYMERASE INHIBITORS V | POLI, POLR2H, POLR2E | HTT 4453/4885TDP1 2687/4885CYP3A4 1830/4885 |
| US-20090060867-A1 | PHOSPHADIAZINE HCV POLYMERASE INHIBITORS III AND VI | POLR2E, POLR2H, POLI | HTT 4552/4885TDP1 2894/4885CYP3A4 1082/4885 |
| US-20090060866-A1 | PHOSPHADIAZINE HCV POLYMERASE INHIBITORS I AND II | POLR2E, POLR2H, POLR2A | HTT 4563/4885TDP1 2607/4885CYP3A4 2214/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.